Date posted: April 3, 2018, 6:00 am
In this episode, we discuss two new agents (valbenazine and deutetrabenazine) -- the first of their kind to receive FDA approval to manage tardive dyskinesia most commonly associated with antipsychotic use.
Date posted: March 13, 2018, 6:00 am
In the previous episodes, we discussed how we should evaluate a patient’s bleeding and clotting risks as well as looked at recommendation for management for various anticoagulants. In this episode, we will continue the discussion to management of antiplatelets as well as when to resume both antiplatelets and anticoagulants following a procedure.
Date posted: February 20, 2018, 6:00 am
In this episode, we will discuss some important factors to consider in management of various anticoagulants. We will also provide agent specific pharmacodynamic and pharmacokinetic based recommendations.
Date posted: January 30, 2018, 6:00 am
In this episode, we discuss the efficacy and safety of probiotics for the prevention of antibiotic-associated diarrhea (AAD) and Clostridium difficile-associated diarrhea (CDAD).
Date posted: January 9, 2018, 6:00 am
In this episode, we will review the surprising results of the VA/DoD’s 2017 Clinical Practice Guidelines on Management of PTSD, particularly as it relates to the use of one particular agent, prazosin.
Date posted: December 19, 2017, 6:00 am
In this episode, we review the important changes in 2017 ACC/AHA guidelines for hypertension management in adults
Date posted: November 28, 2017, 6:00 am
In this episode, we discuss the difficulty in identifying adverse drug reactions (ADR) that ACTUALLY occur from a drug therapy, how tertiary drug references (such as Micromedex or LexiComp) may be misleading, and what tips and tricks you can use to recognize the most clinically relevant ADRs for patient counseling.
Date posted: November 7, 2017, 6:00 am
In this episode, we interview Dylan Moe, PharmD, our very own alumnus, regarding the new Illinois rule requiring patient counseling for all new prescriptions and inquire how the new rule has impacted his pharmacy, work environment, and his opinions on the implementation of the rule.
Date posted: October 17, 2017, 6:00 am
In this episode, we will discuss the current state of benzodiazepine use, expected trends in prescribing, and risks associated with use. Lastly, we will discuss techniques for ensuring that a benzodiazepine taper is performed in a safe manner with lowest risk of harm.
Date posted: September 26, 2017, 6:00 am
In this episode, we discuss new evidence for cardiovascular outcomes in diabetics based on the LEADER trial (liraglutide) and CANVAS trials (canagliflozin). We also discuss the new FDA warning for canagliflozin regarding amputation risk.